Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells

Janeen H. Trembley; Gretchen M. Unger; Vicci L. Korman; Diane K. Tobolt; Zygmunt Kazimierczuk; Lorenzo A. Pinna; Betsy T. Kren; Khalil Ahmed

doi:10.1016/j.canlet.2011.10.007

Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells

Janeen H. Trembley, Gretchen M. Unger, Vicci L. Korman, Diane K. Tobolt, Zygmunt Kazimierczuk, Lorenzo A. Pinna, Betsy T. Kren, Khalil Ahmed

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

CK2, a pleiotropic Ser/Thr kinase, is an important target for cancer therapy. We tested our novel tenfibgen-based nanocapsule for delivery of the inhibitor 2-dimethylamino-4,5,6,7-tetrabromo-1. H-benzimidazole (DMAT) and an siRNA directed against both CK2α and α' catalytic subunits to prostate cancer cells. We present data on the TBG nanocapsule itself and on CK2 inhibition or downregulation in treated cells, including effects on Nuclear Factor-kappa B (NF-κB) p65. By direct comparison of two CK2-directed cargos, our data provide proof that the TBG encapsulation design for delivery of drugs specifically to cancer cells has strong potential for small molecule- and nucleic acid-based cancer therapy.

Original language	English (US)
Pages (from-to)	48-58
Number of pages	11
Journal	Cancer Letters
Volume	315
Issue number	1
DOIs	https://doi.org/10.1016/j.canlet.2011.10.007
State	Published - Feb 1 2012

Bibliographical note

Funding Information:
Grant Sponsors: Department of Veterans Affairs Medical Research Merit Review Funds (K.A.); National Cancer Institute grant numbers UO1-CA15062 (K.A.) and RO1-CA150182 (K.A.); Ministry of Science and Higher Education of Poland, grant N N209 371439 (Z.K.); AIRC, Associazione Italiana per la Ricerca sul Cancro (L.A.P); National Institute of Health grant number R01-DK067436 (B.T.K).

Keywords

CK2
DMAT
Nanocapsule
Nanoparticle
Prostate cancer
Tenfibgen

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.canlet.2011.10.007

Find It

Find It at U of M Libraries

Cite this

@article{3d8a092f3fed49a29a350480bab46c93,

title = "Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells",

abstract = "CK2, a pleiotropic Ser/Thr kinase, is an important target for cancer therapy. We tested our novel tenfibgen-based nanocapsule for delivery of the inhibitor 2-dimethylamino-4,5,6,7-tetrabromo-1. H-benzimidazole (DMAT) and an siRNA directed against both CK2α and α' catalytic subunits to prostate cancer cells. We present data on the TBG nanocapsule itself and on CK2 inhibition or downregulation in treated cells, including effects on Nuclear Factor-kappa B (NF-κB) p65. By direct comparison of two CK2-directed cargos, our data provide proof that the TBG encapsulation design for delivery of drugs specifically to cancer cells has strong potential for small molecule- and nucleic acid-based cancer therapy.",

keywords = "CK2, DMAT, Nanocapsule, Nanoparticle, Prostate cancer, Tenfibgen",

author = "Trembley, {Janeen H.} and Unger, {Gretchen M.} and Korman, {Vicci L.} and Tobolt, {Diane K.} and Zygmunt Kazimierczuk and Pinna, {Lorenzo A.} and Kren, {Betsy T.} and Khalil Ahmed",

note = "Funding Information: Grant Sponsors: Department of Veterans Affairs Medical Research Merit Review Funds (K.A.); National Cancer Institute grant numbers UO1-CA15062 (K.A.) and RO1-CA150182 (K.A.); Ministry of Science and Higher Education of Poland, grant N N209 371439 (Z.K.); AIRC, Associazione Italiana per la Ricerca sul Cancro (L.A.P); National Institute of Health grant number R01-DK067436 (B.T.K).",

year = "2012",

month = feb,

day = "1",

doi = "10.1016/j.canlet.2011.10.007",

language = "English (US)",

volume = "315",

pages = "48--58",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells

AU - Trembley, Janeen H.

AU - Unger, Gretchen M.

AU - Korman, Vicci L.

AU - Tobolt, Diane K.

AU - Kazimierczuk, Zygmunt

AU - Pinna, Lorenzo A.

AU - Kren, Betsy T.

AU - Ahmed, Khalil

N1 - Funding Information: Grant Sponsors: Department of Veterans Affairs Medical Research Merit Review Funds (K.A.); National Cancer Institute grant numbers UO1-CA15062 (K.A.) and RO1-CA150182 (K.A.); Ministry of Science and Higher Education of Poland, grant N N209 371439 (Z.K.); AIRC, Associazione Italiana per la Ricerca sul Cancro (L.A.P); National Institute of Health grant number R01-DK067436 (B.T.K).

PY - 2012/2/1

Y1 - 2012/2/1

N2 - CK2, a pleiotropic Ser/Thr kinase, is an important target for cancer therapy. We tested our novel tenfibgen-based nanocapsule for delivery of the inhibitor 2-dimethylamino-4,5,6,7-tetrabromo-1. H-benzimidazole (DMAT) and an siRNA directed against both CK2α and α' catalytic subunits to prostate cancer cells. We present data on the TBG nanocapsule itself and on CK2 inhibition or downregulation in treated cells, including effects on Nuclear Factor-kappa B (NF-κB) p65. By direct comparison of two CK2-directed cargos, our data provide proof that the TBG encapsulation design for delivery of drugs specifically to cancer cells has strong potential for small molecule- and nucleic acid-based cancer therapy.

AB - CK2, a pleiotropic Ser/Thr kinase, is an important target for cancer therapy. We tested our novel tenfibgen-based nanocapsule for delivery of the inhibitor 2-dimethylamino-4,5,6,7-tetrabromo-1. H-benzimidazole (DMAT) and an siRNA directed against both CK2α and α' catalytic subunits to prostate cancer cells. We present data on the TBG nanocapsule itself and on CK2 inhibition or downregulation in treated cells, including effects on Nuclear Factor-kappa B (NF-κB) p65. By direct comparison of two CK2-directed cargos, our data provide proof that the TBG encapsulation design for delivery of drugs specifically to cancer cells has strong potential for small molecule- and nucleic acid-based cancer therapy.

KW - CK2

KW - DMAT

KW - Nanocapsule

KW - Nanoparticle

KW - Prostate cancer

KW - Tenfibgen

UR - http://www.scopus.com/inward/record.url?scp=81955161863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81955161863&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2011.10.007

DO - 10.1016/j.canlet.2011.10.007

M3 - Article

C2 - 22050909

AN - SCOPUS:81955161863

SN - 0304-3835

VL - 315

SP - 48

EP - 58

JO - Cancer Letters

JF - Cancer Letters

IS - 1

ER -

Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this